Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003247 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 364
- Enrollment target
- 20
- Study locations
NCT03003247 is a Phase 2 study of Acne Vulgaris that has completed, run by Bausch Health Americas. The registered enrollment target is 364 participants, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT03003247, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 364 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Conditions Studied
Interventions
- DRUG IDP-120 Gel
- DRUG IDP 120 Component A Gel
- DRUG IDP 120 Component B Gel
- DRUG IDP 120 Vehicle Gel
Study Locations (20)
Florida
- Valeant Site 13 - Lake Mary
- Valeant Site 16 - Miami
- Valeant Site 14 - Tampa
- Valeant Site 02 - West Palm Beach
Texas
- Valeant Site 07 - Austin
- Valeant Site 12 - Austin
- Valeant Site 18 - San Antonio
New York
- Valreant Site 05 - New York
- Valeant Site 06 - New York
North Carolina
- Valeant Site 01 - Chapel Hill
- Valeant Site 17 - High Point
California
- Valeant Site 15 - Encino
Georgia
- Valeant Site 21 - Atlanta
Indiana
- Valeant Site 23 - South Bend
Michigan
- Valeant Site 09 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003247
The ClinicalTrials.gov registry entry for NCT03003247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (35% higher). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 4 interventions - of which IDP-120 Gel is the first listed.
NCT03003247 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT03003247 about?
NCT03003247 is a clinical study titled "Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris". Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
What is the current status of trial NCT03003247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 364 participants. The study started on 2015-11. Estimated completion is 2016-09-30.
What conditions does trial NCT03003247 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03003247?
The interventions under investigation include: IDP-120 Gel (DRUG), IDP 120 Component A Gel (DRUG), IDP 120 Component B Gel (DRUG), IDP 120 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT03003247?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03003247 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.